

1 **Supporting Information for**

2

3 **Nsp3-N interactions are critical for SARS-CoV-2 fitness and virulence**

4

5 Pengfei Li¹, Biyun Xue², Nicholas J. Schnicker³, Lok-Yin Roy Wong¹, David K. Meyerholz⁴, Stanley
6 Perlman^{1,2*}

7

8 ¹Department of Microbiology and Immunology, University of Iowa, Iowa City, IA, USA.

9 ²Department of Pediatrics, University of Iowa, Iowa City, IA, USA.

10 ³Protein and Crystallography Facility, University of Iowa, Iowa City, IA, USA.

11 ⁴Department of Pathology, University of Iowa, Iowa City, IA, USA.

12

13 **Running title:** NSP3 SARS-Unique Domain S676T mutation alters SARS-CoV-2 fitness.

14 * Corresponding author: Stanley Perlman, stanley-perlman@uiowa.edu

15 Key words: SARS-CoV-2, Nsp3, SARS-unique domain, N protein.

16

17 **This PDF file includes:**

18 Supplementary Materials and Methods

19 Supplementary figures S1-S7 (including legends)

20 Supplementary table S1-S2

21 SI References

22

SI Materials and Methods

23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55

Plasmids

pcDNA3.1-Paip1-Flag (OHu17446) was purchased from GenSmart™. cDNA encoding PAIP1 amplified from pCI-MS2V5-PABPC1 (Addgene plasmid # 65807) with a V5 tag was inserted into pCAGGS mammalian expression vector. The SUD cDNA with either a Myc or Flag tag was amplified from pBAC-SARS-CoV-2 and then cloned into a pCAGGS vector. cDNAs of nsp3 N-terminal part including UBL1, UBL1 to SUD, and of N, with added V5 and Flag tags, were amplified from pBAC-SARS-CoV-2 and cloned into with a pCAGGS vector. pRL-TK (Renilla luciferase) was purchased from Promega (Madison, WI, USA) and modified as follows. Briefly, fragments of SARS-CoV-2 5' UTR and human beta-globin (HBB) were amplified from pBAC-SARS-CoV-2 and pJP-HBB-nLuc (Addgene, plasmid #175431) respectively, and then subcloned to replace the original 5'UTR of pRL-TK Vector. SARS-CoV-2 3' UTR amplified from pBAC-SARS-CoV-2 was positioned downstream of the Renilla luciferase gene in the 5' UTR-containing reporter. Reporter plasmids containing the 5' leader, nsp3-S676T mutants and N-S194L mutants were generated using site-directed mutagenesis as previously described (1). Sequences of all constructs were verified prior to use. All primers are listed in [SI Appendix Supplementary Table S1](#).

Generation of recombinant viruses

All the recombinant viruses in this study were generated based on pBAC-SARS-CoV-2 using lambda red recombination with I-SceI homing endonuclease as previously described (2, 3). Briefly, forward and reverse primers ([SI Appendix Supplementary Table S1](#)) containing overlapping sequences homologous to viral RNA with the desired mutations, flanked by sequences for amplifying a Kan^r-I-SceI fragment were designed and synthesized. PCR products were generated using these primers from pEP-Kan-I-SceI (4) and were electroporated into GS1783 E. coli cells containing pBAC-SARS-CoV-2. Clones containing the desired sequences were selected and treated with arabinose to produce I-SceI, which induced recombination to remove the Kan^r-I-SceI fragment. Desired clones were chloramphenicol-resistant and kanamycin-sensitive and were selected for further verification by sequencing. Vero-E6 cells were grown on 12-well plates to 60–80% confluency and then transfected with recombinant pBAC (1ug) using Lipofectamine 3000. When cytopathic effects (CPE) reached 70%, supernatants were centrifuged to remove cell debris and processed for propagation on Calu-3 2B4 cells. Recombinant viruses were titered on Vero-E6 cells by plaque assay.

56 **Virus infection**

57 All experiments with SARS-CoV-2 were carried out in a Biosafety Level 3 (BSL3) Laboratory at
58 the University of Iowa. Mice were lightly anesthetized with ketamine/xylazine and intranasally
59 inoculated with the indicated amounts of SARS-CoV-2 in DMEM (50 μ L). Mouse was monitored
60 daily to evaluate the weight and mortality. In all cases, mice that did not survive all succumbed to
61 the infection or were sacrificed because they were moribund. No mice were euthanized because
62 they reached a low body weight. Vero-E6/Calu-3 (3×10^5 /well) or human MDMs (5×10^5 /well)
63 were seeded on 12 wells plates for 16h prior to infection. Viruses were inoculated onto cells at
64 the indicated multiplicity of infection (MOI), and plates were gently rocked each 15 min. After 1h,
65 cells were washed by PBS 3 times and cultured in DMEM with 2% FBS. At indicated times, viruses
66 were collected from supernatants and titered by plaque assay. HAEs (5×10^5 /well) were grown
67 in transwells containing collagen-coated 0.4 μ m pore PTFE membranes in 24 well plates. Viruses
68 were inoculated onto the apical sides at 0.1 MOI. After 2h, the inoculum was discarded, and the
69 infected HAEs were washed with PBS. The basal chamber was replaced with fresh culture media.
70 At 24 and 48h post-infection, 200 μ L PBS was added to the apical side of the HAEs and cells
71 were incubated for 30 min at 37°C to collect the released viruses. Viruses were then titered. For
72 virus infection of human macrophages, cells (2×10^5 /well) grown in 24 wells plates were
73 inoculated with 1 MOI of the indicated viruses. Cells were lysed with TRIzol and RNA was
74 prepared for analysis of viral mRNA levels by qPCR. For virus infection in the context of eIF4G
75 or eIF4E knockdown, Vero E6 grown in 12 wells plates were transfected with siRNA targeting
76 eIF4G (sc-35286, Santa Cruz Biotechnology), eIF4E (sc-35284, Santa Cruz Biotechnology) or a
77 negative control using Lipofectamine 3000 (Thermo Fisher Scientific). After 48 h, cells were
78 inoculated with the indicated viruses at 0.05 MOI as described above. At 24 hpi, cells were
79 processed for infectious virus titer and for quantification of viral RNA as described above.

80

81 **Viral plaque assay**

82 Viruses from cell or lung homogenates were serially diluted in DMEM. 200 μ L of diluted viruses
83 were inoculated onto Vero-E6 cells in 12 wells plates for 1h. Plates were gently rocked every 15
84 min. After discarding the inoculum, the infected cells were overlaid with 0.6% agarose containing
85 2% FBS. After 3 days, cells were fixed with 10% formaldehyde, and the plaques were counted
86 after staining with 0.1% crystal violet.

87

88 **Real-time quantitative PCR**

89 Total RNA was extracted from cells lysates or mice lungs using TRIzol reagent (Invitrogen)
90 according to the manufacturer's protocol. DNase-treated RNA (1µg) was subjected to reverse
91 transcription and the resulting cDNA was used to quantify expression of the indicated mRNAs by
92 RT-qPCR. Housekeeping genes GAPDH, and HPRT were used as internal controls to normalize
93 gene expression from cells, and mice, respectively. Average values from duplicates of each gene
94 were used to calculate the relative abundance of transcripts normalized to GAPDH or HPRT and
95 presented as $2^{-\Delta Ct}$. qPCR primers are shown in [SI Appendix Supplementary Table S2](#).

96

97 **Viral genome sequencing**

98 In brief, viruses were inactivated by TRIzol reagent (Invitrogen), and the viral RNA were extracted
99 using the Direct-zol RNA MiniPrep kit (Zymo Research) according to the manufacturer's
100 instructions. ARTIC Version 4 (v4) primers were used for SARS-CoV-2. Nanopore sequencing
101 (Oxford Nanopore Technologies) was performed by the University of Iowa State Hygienic
102 Laboratory.

103

104 **Co-immunoprecipitation and Western blotting assays**

105 HEK-293T cells grown in 10 cm dishes were transfected with the indicated plasmids. After 24 h,
106 cells were lysed with NP40 Cell Lysis buffer containing a protease inhibitor cocktail (Thermo
107 Fisher Scientific). Supernatants were collected and clarified by centrifugation. Cell lysates were
108 treated with Pierce™ Anti-Flag Affinity Resin (Thermo Fisher Scientific) for 2 h at 4°C. Resins
109 were washed 3 times and boiled in 1x Laemmli sample buffer. The immunoprecipitates were
110 subjected to SDS-PAGE followed by Western Blotting as previously described (5). Briefly,
111 proteins separated by SDS-PAGE were transferred to nitrocellulose transfer membranes (Pall
112 Corporation, East Hills, NY). Membranes were blocked with 5% skimmed milk, incubated with the
113 indicated antibodies and visualized using an Odyssey® DLx Infrared Imaging System (LI-COR
114 Biosciences). Primary antibodies used for Western blotting included: anti-Flag rat mAb
115 (Biolegend), anti-V5 and anti-myc mouse mAb (Biolegend), anti-β-actin mouse mAb (Santa Cruz
116 Biotechnology), anti-SARS-CoV-2-N mouse mAb and anti-SARS-CoV-2-N rabbit mAb (Sino
117 Biological), anti-eIF4G and eIF4E mouse mAb (Santa Cruz Biotechnology), anti-Puromycin
118 mouse mAb (Kerafast). IRDye® 800CW goat anti-mouse and IRDye® 800CW goat anti-rabbit
119 IgG secondary antibodies were purchased from LI-COR Biosciences and used as secondary
120 antibodies.

121 **Luciferase assay**

122 HEK-293T cells (5×10^4 /well) were seeded onto 24 well plates, and cells were transfected with the
123 indicated reporter plasmids (0.1 μ g) along with plasmids expressing WT or S676T mutated SUD
124 (1 μ g) or empty control vector (1 μ g) using Lipofectamine 3000 (Thermo Fisher Scientific) for 24h.
125 Cells were lysed using 1x passive lysis buffer (Promega), and luciferase activity was measured
126 using a Renilla luciferase assay kit (Promega) according to the manufacturer's protocol.

127

128 **Human macrophage isolation**

129 Human peripheral blood samples from leukocyte reduction cones were obtained from anonymous
130 (de-identified) volunteers that had consented to blood donation at the DeGowin Blood Center at
131 the University of Iowa. Protocols and consent forms were approved by the University of Iowa's
132 Institutional Review Board. To obtain monocytes, peripheral blood mononuclear cells (PBMCs)
133 were isolated by density gradient centrifugation through Ficoll-Paque PLUS density gradient
134 media (Cytiva) and cultured at a seeding density of 1×10^6 cells/mL in RP-10 media (RPMI-1640
135 medium (GIBCO) with 10% FBS and 2 mM L-glutamine) supplemented with 5 ng/mL macrophage
136 colony-stimulating factor (eBioscience). After 4 days, the cells were washed by Hanks' balanced
137 salt solution (Invitrogen) to remove nonadherent cells. Adherent cells were trypsinized, pelleted,
138 and cultured for 10 days.

139

140 **In silico structural modelling**

141 Amino acids 413-743 of nsp3 from SARS-CoV-2 Wuhan-Hu1 (NC_045512.2) were selected to
142 model the structure of SUD or S676T-SUD using AlphaFold2 in Colab (6). Template mode
143 (pdb70) was chosen since there are multiple solved structures for SUD. Five ranked structures
144 using Amber relaxation were generated for SUD or S676T-SUD. The quality metrics including
145 multiple sequence alignment (MSA) coverage, predicted aligned error (PAE), and predicted local
146 distance difference test (pLDDT) for each group were listed in [SI Appendix Figure S7](#). For the
147 predicted structure of SARS-CoV (NC_004718.3) SUD, the nsp3 amino acid residues 389-720
148 were modeled using AlphaFold2 in Colab as before. The top ranked model of SUD from SARS-
149 CoV or SARS-CoV-2 were used in [Figure 1D](#). The alignment in [Figure 4F](#) was done using the
150 helix residues 662-673 which precede the linker region. Hydrogen bonding analysis ([Fig. 4G](#)) was
151 performed by selecting linker residues 674-678 and 685 and using PyMOL to find polar contacts
152 within the selection for both S676-SUD and T676-SUD. The donor-to-acceptor cut off distance for
153 hydrogen bonds is 3.6 Å in PyMOL.

154 **Histopathological analysis**

155 Paraffin-embedded lung tissues were stained with hematoxylin and eosin (HE) stain. Slides were
156 examined by a boarded pathologist experienced with the model and masked by using a grouped
157 masking approach (2, 7). Edema distribution in the lung were ordinally scored by: 0, none; 1,
158 <25%; 2, 26–50%; 3, 51–75%; and 4, >75% of tissue fields. High resolution images were taken
159 using a BX53 microscope, DP73 digital camera, and Cell Sens Dimension software (Olympus).


160

161 **Statistical analysis**

162 Log-rank (Mantel–Cox) test, two-tailed unpaired t-test with Welch's correction, two-tailed
163 Wilcoxon matched-pairs test, and one-way ANOVA test with Tukey's multiple comparisons test
164 were used in this study as described in the Figure Legends. Data are presented as mean \pm s.e.m.
165 $P < 0.05$ was considered statistically significant. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$; NS, not
166 significant.

167


Fig. S1.



169 **Fig. S1. Alignment of SUD amino acid sequences from different Sarbecoviruses.**

170 The amino acid sequences of SUD from SARS-CoV-2 Wuhan-Hu-1 (NC_045512.2), SARS-CoV
171 Tor2 (NC_004718.3), Bat coronavirus RaTG13(MN996532.2), Bat SARS-like coronavirus
172 WIV1(KF367457.1), Bat SARS-like coronavirus WIV16 (KT444582.1), Bat coronavirus
173 RacCS203 (MW251308.1), Betacoronavirus sp. RpYN06 strain bat/Yunnan/RpYN06/2020, and
174 SARS coronavirus civet007 (AY572034.1) were downloaded from NCBI. The SUD sequence of
175 SARS-CoV-2 with secondary structure information (built by AlphaFold2 in Colab) along with the
176 SUD sequences from the other *Sarbecoviruses* was uploaded to ESPript 3.0 (8) to generate
177 sequence alignment. Acc, accessibility. The amino acid numbers are based on the SARS-CoV-2
178 SUD.


Fig. S2.



180 **Fig. S2. Cytokine expression in mice infected with virus containing NSP3 S676T.**

181 (A) Lung virus titers and sgRNA levels in BALB/c mice infected with 5000 PFU of the indicated
182 viruses at 16 and 24 hpi (n=4). (B) K18-hACE mice were inoculated with 2000 PFU of rWuH-1 or
183 rWuH-1_{Nsp3-S676T}. At 2 and 6 dpi, lungs were harvested to measure viral titers and levels of sgRNA
184 (n=4). (C) BALB/c mice were infected with 5000 PFU of rMA30_{Nsp3-S676T} or rMA30, and total RNA
185 from lungs at 2 and 4 dpi was subject to RT-qPCR to analyze expression of the indicated genes
186 (n=3 mice, representative of two independent experiments). A two-tailed, unpaired t-test with
187 Welch's correction was used to determine statistical significance.

Fig. S3.



188



189

190 **Fig. S3. Effect of IFN-β pre-treatment on virus replication and virus replication after**
191 **infection at low MOI.**

192 (A) Calu-3 cells pretreated with IFN-β (100 U) (PBL Assay Science) or PBS for 16 h were infected
193 with rWuH-1_{Nsp3-S676T} or rWuH-1 (0.05 MOI), At 24 and 48 dpi, supernatants and cell lysates were
194 harvested for assessing virus titer and sgRNA levels, respectively. Representative of 2

195 independent experiments with 3 replicates/experiment. (B) Vero E6 and Calu-3 cells were infected
196 with rWuH-1 or rWuH-1_{Nsp3-S676T} at MOI=0.01. Supernatants were collected at 12, 24, 36 and 72
197 hpi to measure infectious viral titer by plaque assay (n=4 replicates, data combined from two
198 experiments). (C) Vero E6 or Calu-3 cells were infected with 0.01 MOI of rMA30 or rMA30_{Nsp3-}
199 _{S676T}, and viral titers at 24, 36 and 72 hpi from supernatants were measured by plaque assay.
200 Representative of 2 independent experiments with 4 replicates/experiment (B, C). Statistical
201 significance was determined by a two-tailed, unpaired t-test with Welch's correction.

Fig. S4.




203 **Fig. S4. AlphaFold2-based structures of nsp3-S676 and nsp3-T676.**

204 (A) Top 5 ranked structures of the linker region of nsp3-S676 and nsp3-T676. All structures were
205 built by AlphaFold2 in Colab as described in the Methods. Structures were further analyzed
206 using PyMOL. Linker regions between SUD-M and SUD-C are colored in orange. Residues S676
207 and T676 are displayed by stick models. (B) Verification of eIF4G and eIF4E knockdown. Vero
208 E6 cells were transfected with siRNAs targeting eIF4G or eIF4E at 40 nM. After 48h, cells were
209 lysed in 1 x Laemmli buffer for Western blot analysis.

210

Fig. S5.




211

212 **Fig. S5. Further characterization of N-S194L viruses.** (A) Weight and survival of BALB/c mice
 213 infected with 5000 PFU of passage 5 mouse-adapted virus (#1 from Fig. 5B). (n=5) (B) K18-
 214 hACE2 mice infected with 2000 PFU of rWuH-1, rWuH-1_{Nsp3-S676T} or WT_{Nsp3-S676T;N-S194L} were
 215 monitored daily for weight changes and survival (n=4). Log-rank (Mantel-Cox) test were used to
 216 calculate *P* values.


217


Fig. S6.



219 **Fig. S6. The effect of S676T on the interaction of the N-terminal of Nsp3 and N.** (A)
220 Schematic of domain organization of nsp3 and N-terminal nsp3 truncated constructs. The
221 numbers refer to the amino acid sequence of nsp3. Ubl, Ubiquitin-like domain. HVR, hypervariable
222 region. Mac, macrodomain. PLpro, Papain-like protease domain. NAB, nucleic acid-binding
223 domain. β SM, betacoronavirus-specific marker domain. TM, transmembrane domain. Ecto,
224 ectodomain. AH1, amphipathic helix1. Y, unknown function. V5, V5-tag. (B-D) HEK-293T cells
225 were transfected with V5-Ubl1, V5-Ubl1-SUD, V5-Ubl1-S676T-SUD or V5-SUD, individually with
226 Flag-N. Co-transfection of vector and indicated truncated nsp3 constructs were controls. After
227 24h, cells were lysed. Lysates were immunoprecipitated with Pierce™ Anti-Flag Affinity Resin,
228 and subjected to Western blotting analysis (Anti-SARS-CoV-2-N rabbit mAb was used for N
229 protein staining). (E) Effects of N protein on cellular protein synthesis. HEK-293T cells were
230 transfected with plasmids encoding Flag-N, Flag-N-S194L or vector. After 24 h, cells were
231 incubated in medium containing 10 μ g/mL puromycin for 30 min. Cell lysates were subject to
232 western blotting with an anti-puromycin antibody. Data are representative of three independent
233 experiments.
234
235
236

Fig. S7.





238

239

240

Fig. S7. MSA depth/diversity and confidence measures of SUD structure prediction

241 (A-C) MSA coverage (A), pLDDT (B) and PAE (C) for SARS-CoV-2 SUD^{S676} prediction
 242 from AlphaFold2 in Colab. 5 top ranked predicted structures were generated.

243 (D-F) MSA coverage (D), pLDDT (E) and PAE (F) for SARS-CoV-2 SUD^{T676} prediction from
 244 AlphaFold2 in Colab. 5 top ranked predicted structures were generated.

245 (G-I) MSA coverage (G), pLDDT (H) and PAE (I) for SARS-CoV SUD as predicted by AlphaFold2
 246 in Colab. 5 top ranked predicted structures were generated.

247

Supplementary Table S1. Primers for plasmid construction

Primer	5' → 3'
NSP3-S676T(T4547A)-Forward	GATGCTGTTACAGCGTATAATGGTTATCTTACTTCTTCTACTAAA ACACCTGAAGAACATAGGATGACGACGATAAGTAGGG
NSP3-S676T(T4547A)-Reverse	AGTGAGATGGTTTCAATAAAATGTTCTTCAGGTGTTTTAGTAGA AGAAGTAAGATAACCAGCCAGTGTTACAACCAATTAACC
N-S194L(C28854T)-Forward	AAGCCTCTTCTCGTTCCTCATCACGTAGTCGCAACAGTTTAAGA AATTCAACTCCAGGCAAGGATGACGACGATAAGTAGGG
N-S194L(C28854T)-Reverse	AGGAGAAGTTCCCTACTGCTGCCTGGAGTTGAATTTCTTAAAC TGTTGCGACTACGTGAGCCAGTGTTACAACCAATTAACC
PABP1-Forward	CGGATCCACTAGTCCAGTGTGGTGGGCCACCATGGGCAAGCC CATCCCTAACCCACTGCT
PABP1-Reverse	GCTGATCAGCGGGTTTAAACGGGCCTTAAACAGTTGGAACACC GGTGGCACT
SUD-Forward	TCATTTTGGCAAAGAATTGCCACCATGAAAATCAAAGCTTGTGT TGAAGAAG
SUD-Reverse (<i>Myc-tag</i>)	<u>TTTTGGCAGAGGGAAAAAGATCGAGCTCACAGATCCTCTTCTG</u> <u>AGATGAGTTTTTGTTCAGAAAGAAGTGTCTTAAGATTGTCA</u>
N-Forward	TCATTTTGGCAAAGAATTGCCACCATGTCTGATAATGGACCCCA AA
N-Reverse (<i>Flag-tag</i>)	<u>TTTTGGCAGAGGGAAAAAGATCGAGTTACTTGTCGTCATCGTCT</u> <u>TTGTAGTCGGCCTGAGTTGAGTCAGCACTGCT</u>
Ubl1-SUD-Forward (<i>V5-tag</i>)	<u>TCATTTTGGCAAAGAATTGCCACCATGGCAAGCCCATCCCTA</u> <u>ACCCACTGCTGGGCCTGGACAGCACCGCACCAACAAAGGTTA</u> CTTTTG
Ubl1-SUD-Reverse	TTTTGGCAGAGGGAAAAAGATCGAGTCAAGAAAGAAGTGTCTT AAGATTG
Ubl1-Reverse	TTTTGGCAGAGGGAAAAAGATCGAGTCACTCATCTGGAGGGTA GAAAGAA
SUD-Forward (<i>V5-tag</i>)	<u>TCATTTTGGCAAAGAATTGCCACCATGGCAAGCCCATCCCTA</u> <u>ACCCACTGCTGGGCCTGGACAGCACCAAAATCAAAGCTTGTGT</u> TGAAG
SARS-CoV-2 5' UTR-Forward	AAGTTGGTCGTGAGGCACTGGGCAGATTAAGGTTTATACCTT CCCAGGT
SARS-CoV-2 5' UTR-Reverse	CATAAACTTTCGAAGTCATGGTGGCCTTACCTTTCGGTCACACC CGGACG
HBB 5' UTR-Reverse	GGTGTCTGTTTGGAGTTGCTAGTGAACACAGTTGTGTCAGAAG CAAATGTCTGCCAGTGCCCTCACGACCAACTT
HBB 5' UTR-Forward/ (pRL-TK- Forward for assembling with SARS-CoV-2 5' UTR)	GCCACCATGACTTCGAAAGTTTATG
pRL-TK-Reverse for assembling with SARS-CoV-2 5' UTR constructs	CTGCCAGTGCCTCACGACCAACTT
SARS-CoV-2 5' Leader- Forward	GCCACCATGACTTCGAAAGTTTATG
SARS-CoV-2 5' Leader- Reverse	GTTTCGTTTAGAGAACAGATCTACAAGAG
SARS-CoV-2 3' UTR-Forward	CGAGTTCTCAAAAATGAACAATAACAATCTTTAATCAGTGTGTAA CA

SARS-CoV-2 3' UTR-Reverse	TGTATCTTATCATGTCTGCTCGAAGGTCATTCTCCTAAGAAGCT ATTAA
pRL-TK (5' UTR)-Forward for assembling with SARS-CoV-2 3' UTR	CTTCGAGCAGACATGATAAGATACA
pRL-TK (5' UTR)-Reverse for assembling with SARS-CoV-2 3' UTR	TTATTGTTTCATTTTTGAGAACTCG

249

250

251 **Supplementary Table S2. Primers for RT-qPCR**

Primers	5' → 3'
SARS-CoV-2 N-Forward	GACCCCAAATCAGCGAAAT
SARS-CoV-2 N-Reverse	TCTGGTTACTGCCAGTTGAATCTG
SARS-CoV-2 ORF1(Nsp12)-Forward	CCCTGTGGGTTTTACTTAA
SARS-CoV-2 ORF1(Nsp12)-Reverse	ACGATTGTGCATCAGCTGA
Human GAPDH-Forward	GGAGCGAGATCCCTCCAAAAT
Human GAPDH-Reverse	GGCTGTTGTCATACTTCTCATGG
Mouse IFN- α -Forward	TCCATCAGCAGCTCAATGAC
Mouse IFN- α -Reverse	AGGAAGAGAGGGCTCTCCAG
Mouse IFN- β -Forward	TCAGAATGAGTGGTGGTTGC
Mouse IFN- β -Reverse	GACCTTTCAAATGCAGTAGATTCA
Mouse ISG15-Forward	GGCCACAGCAACATCTATGA
Mouse ISG15-Reverse	CGCAAATGCTTGATCACTGT
Mouse TNF-Forward	GAAGTGGCAGAAGAGGCACT
Mouse TNF-Reverse	AGGGTCTGGGCCATAGAACT
Mouse IL-6-Forward	GAGGATACCACTCCCAACAGACC
Mouse IL-6-Reverse	AAGTGCATCATCGTTGTTTCATACA
Mouse CXCL-10-Forward	GCCGTCATTTTCTGCCTCAT
Mouse CXCL-10-Reverse	GCTTCCCTATGGCCCTCATT
Mouse HPRT-Forward	GCGTCGTGATTAGCGATGATG
Mouse HPRT-Reverse	CTCGAGCAAGTCTTTCAGTCC

252
253
254

SI References

- 255 1. P. Li *et al.*, Dysregulation of the RIG-I-like Receptor Pathway Signaling by Peste des Petits
256 Ruminants Virus Phosphoprotein. *J Immunol* **206**, 566-579 (2021).
257 2. L. R. Wong *et al.*, Eicosanoid signalling blockade protects middle-aged mice from severe COVID-
258 19. *Nature* **605**, 146-151 (2022).

259 3. A. R. Fehr, Bacterial Artificial Chromosome-Based Lambda Red Recombination with the I-SceI
260 Homing Endonuclease for Genetic Alteration of MERS-CoV. *Methods Mol Biol* **2099**, 53-68
261 (2020).

262 4. B. K. Tischer, J. von Einem, B. Kaufer, N. Osterrieder, Two-step red-mediated recombination for
263 versatile high-efficiency markerless DNA manipulation in Escherichia coli. *Biotechniques* **40**, 191-
264 197 (2006).

265 5. P. Li *et al.*, The Nucleoprotein and Phosphoprotein of Peste des Petits Ruminants Virus Inhibit
266 Interferons Signaling by Blocking the JAK-STAT Pathway. *Viruses* **11** (2019).

267 6. M. Mirdita *et al.*, ColabFold: making protein folding accessible to all. *Nat Methods* **19**, 679-682
268 (2022).

269 7. D. K. Meyerholz, A. P. Beck, Principles and approaches for reproducible scoring of tissue stains in
270 research. *Lab Invest* **98**, 844-855 (2018).

271 8. X. Robert, P. Gouet, Deciphering key features in protein structures with the new ENDscript
272 server. *Nucleic Acids Res* **42**, W320-324 (2014).